Resistance to therapy caused by intragenic deletion in BRCA2 (original) (raw)

• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005)
  Article CAS ADS Google Scholar
• Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005)
  Article CAS ADS Google Scholar
• Tutt, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20, 4704–4716 (2001)
  Article CAS Google Scholar
• Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 263–272 (2001)
  Article CAS Google Scholar
• Domchek, S. M. & Weber, B. L. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25, 5825–5831 (2006)
  Article CAS Google Scholar
• Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864–5874 (2006)
  Article CAS Google Scholar
• Davies, O. R. & Pellegrini, L. Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat. Struct. Mol. Biol. 14, 475–483 (2007)
  Article Google Scholar
• Esashi, F., Galkin, V. E., Yu, X., Egelman, E. H. & West, S. C. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat. Struct. Mol. Biol. 14, 468–474 (2007)
  Article CAS Google Scholar
• Ratnam, K. & Low, J. A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13, 1383–1388 (2007)
  Article CAS Google Scholar
• Goggins, M. et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360–5364 (1996)
  CAS PubMed Google Scholar
• Yang, H. et al. BRCA2 function in DNA binding and recombination from a BRCA2–DSS1-ssDNA structure. Science 297, 1837–1848 (2002)
  Article CAS ADS Google Scholar
• Spain, B. H., Larson, C. J., Shihabuddin, L. S., Gage, F. H. & Verma, I. M. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc. Natl Acad. Sci. USA 96, 13920–13925 (1999)
  Article CAS ADS Google Scholar
• Abaji, C., Cousineau, I. & Belmaaza, A. BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis. Cancer Res. 65, 4117–4125 (2005)
  Article CAS Google Scholar
• McCabe, N. et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-ribose) polymerase: an issue of potency. Cancer Biol. Ther. 4, 934–936 (2005)
  Article CAS Google Scholar
• Tutt, A. N. et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 139–148 (2005)
  Article CAS Google Scholar
• Furuta, T. et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 278, 20303–20312 (2003)
  Article CAS Google Scholar
• Weinstock, D. M., Elliott, B. & Jasin, M. A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. Blood 107, 777–780 (2006)
  Article CAS Google Scholar
• Saeki, H. et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl Acad. Sci. USA 103, 8768–8773 (2006)
  Article CAS ADS Google Scholar
• Cass, I. et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97, 2187–2195 (2003)
  Article CAS Google Scholar
• Pal, T., Permuth-Wey, J., Kapoor, R., Cantor, A. & Sutphen, R. Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer 6, 113–119 (2007)
  Article CAS Google Scholar
• Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nature Rev. Drug Discov. 4, 307–320 (2005)
  Article CAS Google Scholar
• Hirschhorn, R. In vivo reversion to normal of inherited mutations in humans. J. Med. Genet. 40, 721–728 (2003)
  Article CAS Google Scholar
• Xia, B. et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nature Genet. 39, 159–161 (2007)
  Article CAS Google Scholar
• Daniels, M. J., Wang, Y., Lee, M. & Venkitaraman, A. R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306, 876–879 (2004)
  Article CAS ADS Google Scholar
• Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocols 1, 1112–1116 (2006)
  Article CAS Google Scholar
• Gudmundsdottir, K., Lord, C. J., Witt, E., Tutt, A. N. & Ashworth, A. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep. 5, 989–993 (2004)
  Article CAS Google Scholar
• Reis-Filho, J. S. et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 207, 1–13 (2005)
  Article CAS Google Scholar
• Poch, G. & Pancheva, S. N. Calculating slope and ED50 of additive dose–response curves, and application of these tabulated parameter values. J. Pharmacol. Toxicol. Methods 33, 137–145 (1995)
  Article CAS Google Scholar
• Bertwistle, D. et al. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res. 57, 5485–5488 (1997)
  CAS PubMed Google Scholar
• Lambros, M. B. et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab. Invest. 86, 398–408 (2006)
  Article CAS Google Scholar